Using several different in vitro readout systems, we compare the functions of two TLR9 agonists in clinical development for cancer therapy, dSLIM® and ProMune®, differing in sequence, chemical composition, and structure (Figs. 1 and 2). The gene discussed is TLR9; the disease is cancer.